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It is estimated that there are 3,500-7,000 deaths per year from alcoholic hepatitis and/or cirrhosis in the UK 1, 2 . The incidence of cirrhosis in alcoholics at autopsy is about10%. The average intake of alcohol in male and female alcoholics with cirrhosis is about 175 g/day and 120 g/day, respectively, for approximately eight years, although any alcohol consumption in excess of 60-80 g/day should cause concern. There is evidence of alcoholic hepatitis on liver biopsy in 30-60% of inpatients with alcoholic liver disease, and many patients presenting with alcoholic hepatitis have established cirrhosis at the time of diagnosis. However, the hepatitic element is a clinically reversible entity.
Metabolism of alcohol
Alcohol is oxidised in the liver or stomach by alcohol dehydrogenase to acetaldehyde, which is then metabolised to acetate. It can be oxidised further through the citric acid cycle, or act as a precursor for the synthesis of fatty acids and fat. There are approximately 600 cal in a bottle of wine, one gram of alcohol providing about seven calories. Chronic alcohol abuse will result in induction of the microsomal P450 ethanol oxidising system. P450 2E1 isoenzyme is the major P450 enzyme involved; it usually metabolises 10-15% of alcohol consumed. Microsomal oxidation of alcohol will generate reactive oxygen species or free radicals. These need to be inactivated or removed by a variety of scavenging or metabolising mechanisms such as catalase, glutathione peroxidase, vitamin C or vitamin E.
Pathogenesis
The pathogenesis of alcoholic liver disease involves the generation of reactive oxygen species which cause lipid peroxidation and secondary protein modification. Modified proteins may then act as foreign proteins and initiate an inflammatory response. Alcohol also increases the intestinal absorption of endotoxins and secondary activation of a variety of pro-inflammatory and profibrotic cytokines. The combination of activated cytokines and altered cellular epitopes initiates hepatic inflammation and stellate cell activation. Malnutrition, causing depletion of cellular glutathione stores in alcoholics, aggravates this pro-inflammatory cascade (Fig 1) .
Pathology
The typical pathological features of alcoholic hepatitis are shown in Table 1 .
Presentation of alcoholic liver disease
Patients with alcohol abuse may be asymptomatic but present with abnormal liver enzymes on routine blood tests and an enlarged liver. Clinically, they may be indistinguishable from patients with mild alcoholic hepatitis or even silent alcoholic cirrhosis. Cirrhosis frequently develops silently, and is manifest only when the patient develops hepatic decompensation with ascites or variceal haemorrhage.
Presentation of alcoholic hepatitis
Alcoholic hepatitis usually presents as an onset of malaise and jaundice, often with anorexia, nausea and vomiting. Patients have usually lost a considerable amount of weight and malnutrition is present in about 90%. There may be a dull ache over the liver. Many have stopped drinking recently, suggesting that a prodromal phase discourages further imbibing. Clinically, there are usually florid stigmata of chronic liver disease such as spider naevi and facial telangiectasia. Pyrexia is frequently present. Many patients develop ascites, but this may be absent even in severe cases. Acute alcoholic hepatitis is often confused with viral hepatitis, but florid spider naevi, a very large liver, typical biochemistry (see below) and frequent leukocytosis are diagnostic markers of acute alcoholic hepatitis (Fig 2) . T his may present with fatty liver, cirrhosis or acute alcoholic hepatitis. A lcoholic hepatitis may itself be asymptomatic or develop into a cholestatic syndrome. T he presence of moderate or severe alcoholic hepatitis is serious as the associated mortality is high. Despite use of the term 'alcoholic hepatitis' , it is often not realised that alcoholic hepatitis is different biochemically from the situation in viral hepatitis. Thus, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are usually below 200 U/l, with AST higher than ALT. If transaminase activity exceeds this, alternative diagnoses should be considered. The characteristic biochemical and haematological features in a patient with alcoholic hepatitis are shown in Table 2 . For example, a patient with alcoholic hepatitis might have a bilirubin level of 540 mmol/l, albumin 26 g/l, alkaline phosphatase 170 U/l, AST 78 U/l and ALT 35U/l.
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Prognosis
The prognosis of alcoholic hepatitis is variable. The short-term mortality (<3 months) ranges from 15-55% for those with mild and severe alcoholic hepatitis, respectively [3] [4] [5] [6] [7] [8] . Severity is usually assessed by calculating the discriminant function (DF), as described by Maddrey and colleagues 5 , a DF score of over 32 indicating severe disease. In the UK, mortality is currently 50% in patients with a DF above 32 (recent analysis of 241 patients from several centres: unpublished observation). DF is calculated as follows: DF = (bilirubin/17) + (prolongation of prothrombin time x 4.6). Thus, for a patient with a bilirubin level of 540 mmol/l, DF = (540/17) + ((23-13) x 4.6) = 20 + 46 = 66.
Management of alcoholic hepatitis
General measures
The following should be undertaken in all patients:
Admission to hospital unless the disease is mild and there is a good abstinent home environment. Screening for bacterial infections, including an ascitic fluid tap as appropriate, with a low threshold for starting antibiotics. Infections occur in 40% of those admitted with severe alcoholic hepatitis and cause 30% of all deaths 9 . Assessment of nutritional status by a dietitian and nutritional support given as necessary, including nasogastric or intravenous feeding. A low protein diet should not be given even if severe hepatic encephalopathy is present. The current European Society for Parenteral and Enteral Nutrition (ESPEN) guidelines recommend that patients are given about 35 kcal/kg/day, 1.5 g/kg/day as protein 10 . Daily monitoring of liver and renal function until there is a consistent improvement of liver function tests (the incidence of development of the hepatorenal syndrome is high in those who continue to deteriorate).
Specific therapies
Steroids. At present, there is no universally accepted treatment of alcoholic hepatitis, although most liver centres currently ensure that patients receive good nutrition and are given a trial of steroids, usually prednisolone 40 mg/day for one month. The 14 published studies of steroid therapy for alcoholic hepatitis since 1971 have been subjected to a number of systematic reviews and metaanalyses 8 . Most of the clinical trials have found no overall benefit from steroid treatment, whereas some of the metaanalyses have found a slight benefit of steroid therapy 11, 12 .
The major problem with the metaanalyses has been the grouping together of a heterogeneous group of trial protocols. This includes the most recent, and currently widely quoted, meta-analysis which found no benefit for steroids. Although there was a trend of benefit with steroids, the results were not statistically significant (p = 0.2) despite the publication bias favouring steroid treatment 8 . The most recent and successful steroid trial has been the subject of two reports 4, 13 . Overall survival at six months in the groups treated with steroids was 73% and 84%, compared with 41% in the placebo group (p = 0.02). However, by two years the mortality in all three groups was identical. Thus, in this study, prednisolone was associated with a short-term improvement in mortality in patients with histologically proven severe alcoholic hepatitis (DF >32). The largest study (263 patients), which also included patients with moderate alcoholic hepatitis, evaluated three treatments (steroids, placebo and oxandrolone) and found no survival benefit on steroids. Indeed, the mortality at two months in the group with severe alcoholic hepatitis given steroids (48%) was not significantly different from those given placebo (33%) 3 . At one year the cumulative mortality in the two groups was 62% (placebo) and 58% (steroids).
Thus, although the use of steroids in alcoholic hepatitis is to some extent still contentious, and further studies are required, at present the mainstay of treatment is abstinence, nutritional support and short-term steroid therapy.
Other treatments. A variety of other treatments has been tried in alcoholic hepatitis (Table 3) . Some may have shown improvements, but the absence of further studies and the abandonment of their use suggests that they are ineffective.
Complications of alcoholic hepatitis
Alcoholic hepatitis may follow an inexorably progressive course, with progressive jaundice and liver failure. Patients die usually from liver failure with a combination of hepatorenal syndrome plus or minus variceal haemorrhage, plus or minus infections such as spontaneous bacterial peritonitis. Most patients develop hepatic encephalopathy with progressive disease. The development of hepatorenal syndrome carries a high mortality. Apart from measures to improve renal function such as fluid support, pressor support (eg glypressin) 14 with or without N-acetylcysteine 15 , renal support with haemodialysis or haemofiltration should be considered. The survival of patients with alcoholic hepatitis undergoing dialysis is about 12%. Although these survival figures are poor, in this author's view renal support should be given to most patients with alcoholic hepatitis and hepatorenal syndrome if other organs are functioning well. For those requiring ventilation, the mortality is very high and dialysis probably just prolongs dying.
